ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2018
Nontuberculous mycobacterial disease managed within UK primary care, 2006-2016.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- Nontuberculous Mycobacterial Lung Disease Management in Belgium: A Longitudinal Pharmacy Database Study.Drugs - real world outcomes · 2025Article
- Infection by Clonally RelatedAmerican journal of respiratory and critical care medicine · 2025Article
- Paediatric cervicofacial lymphadenitis caused by non-tuberculous mycobacteria: nation-wide overview in the period 2000-2020.BMC pediatrics · 2025Article
- Insights from the European Nontuberculous mycobacterial pulmonary disease PAtient Disease Experience (ENPADE) survey- exploring disease burden and impact.BMC pulmonary medicine · 2025Article
- Pulmonary Delivery of Antibiotics to the Lungs: Current State and Future Prospects.Pharmaceutics · 2025Review
- Supporting Patients with Nontuberculous Mycobacterial Pulmonary Disease: Ensuring Best Practice in UK Healthcare Settings.Pharmacy (Basel, Switzerland) · 2024Review
- Global Epidemiology of Nontuberculous Mycobacterial Pulmonary Disease: A Review.Clinics in chest medicine · 2023Review
- Whole genome sequencing and prediction of antimicrobial susceptibilities in non-tuberculous mycobacteria.Frontiers in microbiology · 2022Review
- The epidemiology of nontuberculous mycobacterial pulmonary disease in the Netherlands.ERJ open research · 2021Article
- Physical Measures to Reduce Exposure to Tap Water-Associated Nontuberculous Mycobacteria.Frontiers in public health · 2020Article
- Incidence, comorbidities, and treatment patterns of nontuberculous mycobacterial infection in South Korea.Medicine · 2019Observational
- Potential therapeutic effect of ninjinyoeito for the treatment of pulmonary nontuberculous mycobacterial infections: A case report.Journal of family medicine and primary care · 2019Article
- Prevalence, incidence, and mortality of nontuberculous mycobacterial infection in Korea: a nationwide population-based study.BMC pulmonary medicine · 2019Article
- Risk factors and secondary care utilisation in a primary care population with non-tuberculous mycobacterial disease in the UK.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2019Article
- Diversity of Nontuberculous Mycobacteria in Kuwait: Rapid Identification and Differentiation of Mycobacterium Species by Multiplex PCR, INNO-LiPA Mycobacteria v2 Assay and PCR Sequencing of rDNA.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous UK studies investigating nontuberculous mycobacteria have been limited to reporting isolation from culture, not burden of disease. We assessed the burden of nontuberculous mycobacterial disease (NTMD) in UK primary care from 2006 to 2016. Using electronic healthcare records, we identified patients with NTMD using a strict definition including patients with guideline-directed treatment/monitoring. We described treatment regimens and incidence/prevalence in the general population and in patients with underlying chronic respiratory diseases. Incidence of primary care-managed NTMD in the general population decreased (2006 to 2016 rates per 100,000 person-years, 3.85 to 1.28). Average annual prevalence of NTMD in the general population was 6.38 per 100,000. Around 85% were taking antimycobacterial therapy; 53.2% were taking a guideline-recommended regimen. Incidence of NTMD in patients with respiratory disease decreased (2006 to 2016 rates per 100,000 person-years, 12.5 to 7.40). Average annual prevalence of NTMD in patients with respiratory disease was 27.7 per 100,000. This is the first UK study using nationally representative data to investigate the burden of NTMD managed within primary care. Incidence and prevalence of managed NTMD within primary care is gradually declining. Increasing complexity in the management of NTMD may be driving a shift in care to secondary settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.